ElectroCore, Inc. 2022 First-Quarter Form 10-Q Summary
Business Context and Reporting Period
ElectroCore is a commercial-stage medical device company developing and selling gammaCore, a non-invasive vagus nerve stimulation therapy initially focused on primary headache conditions. The report covers the three months ended March 31, 2022, and was filed May 5, 2022. The financial statements are unaudited and prepared under U.S. GAAP.
Key Financial Metrics
| Metric | Q1 2022 | Q1 2021 | Change |
|---|---|---|---|
| Net sales | $1.899 million | $1.204 million | +$0.695 million, or 58% |
| Gross profit | $1.539 million | $0.840 million | +$0.699 million |
| Gross margin | 81% | 70% | +11 percentage points |
| Operating expenses | $7.120 million | $6.224 million | +$0.896 million |
| Loss from operations | $(5.581) million | $(5.384) million | Loss increased $0.197 million |
| Net loss | $(5.582) million | $(5.384) million | Loss increased $0.198 million |
| Basic and diluted loss per share | $(0.08) | $(0.11) | Improved due primarily to higher share count |
| Cash used in operating activities | $(4.780) million | $(4.156) million | Use increased $0.624 million |
| Cash and cash equivalents at period-end | $29.882 million | $9.064 million | Prior-year amount was lower following financing activity timing |
U.S. revenue was $1.594 million versus $0.824 million in the prior-year period. United Kingdom revenue was $0.266 million versus $0.317 million. The VA/DoD channel represented 66.4% of sales, while the U.K. National Health Service represented 13.0%.
As of March 31, 2022, total assets were $37.181 million, total liabilities were $5.365 million, and stockholders’ equity was $31.816 million. Current assets were $32.494 million versus current liabilities of $4.683 million. The balance sheet had no reported conventional long-term debt; liabilities principally consisted of accounts payable, accrued obligations, operating lease liabilities and an insurance-premium financing arrangement. Operating lease liabilities totaled $0.746 million.
Material Changes Versus the Prior Comparable Period
- Sales increased 58%, driven by a $0.770 million increase from the VA and U.S. commercial channels, partly offset by a $0.075 million decrease in non-U.S. sales, principally due to COVID-19 effects in the United Kingdom.
- Gross margin improved to 81% from 70%. Management attributed the improvement to cash-pay licensing models, recognition of starter-device costs over estimated useful lives, a higher mix of longer-duration therapies, and favorable labor and overhead absorption.
- Research and development expense increased 87% to $0.934 million due to product development, investigator-initiated trials and scientific publications.
- Selling, general and administrative expense increased 8% to $6.186 million as the company invested in commercial activities.
- Operating cash burn increased to $4.780 million from $4.156 million. Unlike Q1 2021, there was no financing cash inflow; Q1 2021 included $6.920 million from common-stock issuance.
- Cash declined from $34.689 million at December 31, 2021 to $29.882 million at March 31, 2022, primarily reflecting operating cash use.
Guidance, Outlook, Risks and Unusual Items
- The company has suspended its earlier full-year revenue guidance since March 2020 and did not provide reinstated quantitative revenue guidance in this filing.
- Management expects continued losses and negative operating cash flow for at least the next several years while it seeks broader adoption of gammaCore.
- Management expects research and development and selling, general and administrative expenses to increase during the remainder of 2022, including spending on a next-generation therapy delivery platform and commercial expansion.
- The company expects most 2022 revenue to continue coming from VA/DoD and the United Kingdom, while pursuing direct-to-consumer and direct-to-physician cash-pay models and additional international distribution.
- Management believes existing cash will fund currently planned operating and capital requirements for at least 12 months from issuance of the financial statements. Beyond that period, additional financing may be required or activities may need to be curtailed.
- On March 29, 2022, the company entered into an agreement with Teijin Limited granting exclusive Japanese commercialization rights for certain nVNS indications. The agreement includes a non-refundable upfront payment, potential milestones, annual license fees and possible future supply arrangements, but the filing text does not provide a clear value for the upfront payment or milestones.
- On April 14, 2022, after quarter-end, the company received approximately $445,000 from the sale of New Jersey net operating losses.
- COVID-19 continued to restrict sales-force access to prescribing physicians and patients and adversely affected the U.K. business. Supply-chain, healthcare-provider access, market acceptance, reimbursement, regulatory and competitive risks remain material.
- The company disclosed shareholder securities litigation and derivative litigation. The matters remain at preliminary or unresolved stages, and the company could not estimate the probability or range of potential loss; no accrual was recorded.
- Nasdaq notified the company that its common stock had traded below the $1.00 minimum bid price for 30 consecutive business days. The initial compliance deadline was June 20, 2022. The company intended to seek transfer to the Nasdaq Capital Market and may need a reverse stock split if compliance is not otherwise achieved.
Important Facts for Investors to Verify
- Whether revenue growth is sustained and becomes less dependent on VA/DoD and other concentrated customers.
- Whether the improved 81% gross margin persists as product mix, pricing and starter-device accounting assumptions change.
- The pace of cash consumption, the company’s ability to remain funded beyond the stated 12-month runway and any use of its $75 million shelf registration statement.
- The actual economic value and commercial milestones associated with the Teijin Japan license.
- The effect of COVID-19, reimbursement conditions and direct-to-consumer or direct-to-physician initiatives on adoption.
- The status and potential financial exposure of shareholder litigation and derivative actions.
- Compliance with Nasdaq minimum bid-price and other continued-listing requirements.